Core fucosylation has been identified as a potential therapeutic target for inflammatory bowel disease, and decreased core fucosylation in CD4+ T cells has shown a protective effect on the course of T cell-mediated colitis (49). This evidence concerns the gene CD4 and inflammatory bowel disease.